Որոնման արդյունքները - David Floch
- Ցուցադրվում են 1 - 3 արդյունքները 3
-
1
Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody Abhijit Chakraborty, Stacey Tannenbaum, Christiane Rordorf, Philip J. Lowe, David Floch, Hermann Gram, Sandip Kumar Roy
Հրապարակվել է 2012Revisão -
2
Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects Jonathan Arnold A. P., I. Bottoli, Andrej Skerjanec, David Floch, A. Groenewegen, Suzanne Maahs, Claire Owen, Ieuan Jones, Philip J. Lowe
Հրապարակվել է 2014Artigo -
3
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study Benjamin A. Fisher, Antónia Szántó, Wan‐Fai Ng, Stefano Bombardieri, Maximilian Posch, Athena Papas, Arwa M. Farag, Thomas Daikeler, Bettina Bannert, Diego Kyburz, Alan Kivitz, Steven E. Carsons, David Isenberg, Francesca Barone, Simon Bowman, Pascal Espié, David Floch, Cyrielle Dupuy, Xiaohui Ren, P. Faerber, A. Wright, Hans Hockey, Michael Rotte, Julie Milojevic, Alexandre Avraméas, Marie‐Anne Valentin, James S. Rush, P Gergely
Հրապարակվել է 2020Artigo
Որոնման գործիքներ:
Առնչվող խորագիր
Internal medicine
Medicine
Alternative medicine
Gastroenterology
Immunology
Pathology
Pharmacodynamics
Pharmacokinetics
Pharmacology
Placebo
Adverse effect
Allergen
Allergy
Anakinra
Antibody
Basophil
Canakinumab
Clinical endpoint
Clinical trial
Cohort
Disease
Dosing
Immunoglobulin E
Interim analysis
Omalizumab
Psoriasis
Rheumatoid arthritis
Surgery
Tolerability